Literature DB >> 26199298

Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis.

Ana Torres Oliveira1, Sandra Lopes1, Maria Augusta Cipriano2, Carlos Sofia1.   

Abstract

A 33-year-old woman with multiple sclerosis, medicated with high doses of methylprednisolone, cyclophosphamide and glatiramer acetate, was referred to our department due to acute liver injury. The laboratory investigation was normal except for weakly positive antinuclear antibodies. Cyclophosphamide and glatiramer acetate were suspended, and intravenous immunoglobulin with maintenance of high doses of methylprednisolone was initiated. The patient developed another episode of acute hepatitis so the immunoglobulin was stopped. After that, she had three more episodes of elevation of liver enzymes with no hepatic insufficiency while medicated only with high doses of methylprednisolone. At this time, liver biopsy showed focal centrilobubar hepatocyte necrosis with minimal interface hepatitis. After the high doses of methylprednisolone were suspended, the patient remained asymptomatic, with normal hepatic enzymes. This case emphasises that, although rare, induced liver injury after high doses of methylprednisolone can occur. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26199298      PMCID: PMC4513529          DOI: 10.1136/bcr-2015-210722

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Liver injury caused by drugs: an update.

Authors:  Guido Stirnimann; Kerstin Kessebohm; Bernhard Lauterburg
Journal:  Swiss Med Wkly       Date:  2010-09-24       Impact factor: 2.193

2.  Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.

Authors:  Einar Björnsson; Jayant Talwalkar; Sombat Treeprasertsuk; Patrick S Kamath; Naoki Takahashi; Schuyler Sanderson; Matthias Neuhauser; Keith Lindor
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

3.  Drug induced liver injury and its relationship to autoimmune hepatitis.

Authors:  Christina Weiler-Normann; Christoph Schramm
Journal:  J Hepatol       Date:  2011-03-09       Impact factor: 25.083

Review 4.  Mechanisms of drug-induced liver injury.

Authors:  Michael P Holt; Cynthia Ju
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 5.  Drug-induced liver injury: Interactions between drug properties and host factors.

Authors:  Minjun Chen; Ayako Suzuki; Jürgen Borlak; Raúl J Andrade; M Isabel Lucena
Journal:  J Hepatol       Date:  2015-04-22       Impact factor: 25.083

6.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

Review 7.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

8.  Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy.

Authors:  Martin Eggert; Robert Goertsches; Ulrike Seeck; Silvia Dilk; Gunther Neeck; Uwe K Zettl
Journal:  J Neurol Sci       Date:  2007-09-24       Impact factor: 3.181

Review 9.  High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature.

Authors:  H M A D'Agnolo; J P H Drenth
Journal:  Neth J Med       Date:  2013-05       Impact factor: 1.422

10.  Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature.

Authors:  Krzysztof Gutkowski; Alina Chwist; Marek Hartleb
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

View more
  5 in total

1.  Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.

Authors:  Miguel Eugenio Zoubek; José Pinazo-Bandera; Aida Ortega-Alonso; Nelia Hernández; Javier Crespo; Fernando Contreras; Inmaculada Medina-Cáliz; Judith Sanabria-Cabrera; Rocío Sanjuan-Jiménez; Andrés González-Jiménez; Miren García-Cortés; M Isabel Lucena; Raúl J Andrade; Mercedes Robles-Díaz
Journal:  United European Gastroenterol J       Date:  2019-03-24       Impact factor: 4.623

Review 2.  Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Authors:  David E Kleiner
Journal:  Surg Pathol Clin       Date:  2018-06

Review 3.  Natalizumab in Multiple Sclerosis: Long-Term Management.

Authors:  Marinella Clerico; Carlo Alberto Artusi; Alessandra Di Liberto; Simona Rolla; Valentina Bardina; Pierangelo Barbero; Stefania Federica De Mercanti; Luca Durelli
Journal:  Int J Mol Sci       Date:  2017-04-29       Impact factor: 5.923

Review 4.  Glucocorticoid Treatment Strategies in Liver Failure.

Authors:  Chao Ye; Wenyuan Li; Lei Li; Kaiguang Zhang
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

5.  Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients.

Authors:  Viviana Nociti; Marco Biolato; Chiara De Fino; Assunta Bianco; Francesco Antonio Losavio; Matteo Lucchini; Giuseppe Marrone; Antonio Grieco; Massimiliano Mirabella
Journal:  Brain Behav       Date:  2018-05-04       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.